Application of the combined FibroMeter vibration‐controlled transient elastography algorithm in Chinese patients with non‐alcoholic fatty liver disease

Loong, Thomson Chi‐Wang; Wei, Jeremy Lok; Leung, Jonathan Chung‐Fai; Wong, Grace Lai–Hung; Shu, Sally She‐Ting; Chim, Angel Mei‐Ling; Chan, Anthony W.H.; Choi, Paul Cheung–Lung; Tse, Yee‐Kit; Wong, Vincent Wai‐Sun

doi:10.1111/jgh.13671

Cited by 47 publications

(43 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The TE‐M probe showed excellent negative predictive values, but modest PPVs (71.4% in F2‐F4 and 61.0% in F3‐F4). Therefore, in patients with a relatively high liver stiffness, the combination of the TE‐M probe with FibroMeter vibration‐controlled TE achieved greater accuracy in diagnosing AF than did TE alone (PPVs from 71.4% to 84.4% for F2‐F4 and from 61.0% to 88.9% for F3‐F4) . It is noteworthy that the substantial heterogeneity in the population and evaluation endpoints may lead to variations in the diagnostic accuracy (Supporting Table ).…”

Section: Resultsmentioning

confidence: 99%

Unexpected Rapid Increase in the Burden of NAFLD in China From 2008 to 2018: A Systematic Review and Meta‐Analysis

et al. 2019

View full text Add to dashboard Cite

With rapid lifestyle transitions, the increasing burden of nonalcoholic fatty liver disease (NAFLD) in China has emerged as a major public health issue. To obtain a comprehensive overview of the status of NAFLD over the past decade, we evaluated the epidemiology, risk factors, complications, and management of NAFLD in China through a systematic review and meta‐analysis. Five English literature databases and three Chinese databases were searched for relevant topics from 2008 to 2018. A total of 392 studies with a population of 2,054,554 were included. National prevalence of NAFLD was 29.2%, with a heavier disease burden among the middle‐aged, males, those in northwest China and Taiwan, regions with a gross domestic product per capita greater than 100,000 yuan, and Uygur and Hui ethnic groups. Currently, original studies on natural history and complications of NAFLD in China are scarce. Several studies revealed that NAFLD is positively correlated with the incidence of extrahepatic tumors, diabetes, cardiovascular disease and metabolic syndrome. The Chinese population may have a higher hereditary risk of NAFLD due to more frequent nonsynonymous mutations in genes regulating lipid metabolism. Ultrasonography is the primary imaging tool in the detection of NAFLD in China. Serum tests and risk stratification algorithms for staging NAFLD remain under investigation. Specific pharmaceutical treatments for NAFLD are still undergoing clinical trials. It is noteworthy that the Chinese are underrepresented compared with their proportion of the NAFLD population in such trials. Conclusion: China experienced an unexpected rapid increase in the burden of NAFLD over a short period. Rising awareness and urgent actions need to be taken in order to control the NAFLD pandemic in China.

show abstract

Section: Resultsmentioning

confidence: 99%

Unexpected Rapid Increase in the Burden of NAFLD in China From 2008 to 2018: A Systematic Review and Meta‐Analysis

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The FibroMeter tests include the FibroMeter VCTE which is a combination of blood markers with the Fibroscan result (Echosens) in a single formula (Table S1 and Table ). Recent studies have demonstrated that the combinatory FibroMeter VCTE outperforms blood fibrosis tests and Fibroscan for the non‐invasive evaluation of liver fibrosis in NAFLD . Used as second‐line procedure after blood fibrosis tests or Fibroscan, the FibroMeter VCTE decreases the rate of patients with undetermined diagnosis by twofold …”

Section: Discussionmentioning

confidence: 99%

“…Independent studies have confirmed the good diagnostic accuracy of the FibroMeter NAFLD (Table ). Some of these works showed the FibroMeter NAFLD to have an accuracy comparable to the simple blood fibrosis tests FIB4 and NAFLD fibrosis score (NFS), whereas other works found the FibroMeter NAFLD to be significantly more accurate . The FibroMeter V2G , developed for the diagnosis of significant fibrosis in chronic hepatitis C, includes both indirect (AST, urea, platelets, prothrombin time) and direct (hyaluronate, alpha2‐macroglobulin) markers of liver fibrosis.…”

Section: Introductionmentioning

confidence: 99%

“…Some of these works showed the FibroMeter NAFLD to have an accuracy comparable to the simple blood fibrosis tests FIB4 and NAFLD fibrosis score (NFS), [15][16][17] whereas other works found the FibroMeter NAFLD to be significantly more accurate. 17,18 The FibroMeter V2G , developed for the diagnosis of significant fibrosis in chronic hepatitis C, 19 includes both indirect (AST, urea, platelets, prothrombin time) and direct (hyaluronate, alpha2-macroglobulin) markers of liver fibrosis. We have recently compared the FibroMeter NAFLD , the FibroMeter V2G , four simple blood fibrosis tests (APRI, FIB4, BARD, NFS) and two other specialized blood fibrosis tests (Fibrotest, Hepascore) in a large cohort of 452 biopsy-proven NAFLD patients.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Direct comparison of the specialised blood fibrosis tests FibroMeter^V2G and Enhanced Liver Fibrosis score in patients with non‐alcoholic fatty liver disease from tertiary care centres

Guillaume

Moal

Delabaudière

et al. 2019

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Summary Background The Enhanced Liver Fibrosis score (ELF) and the FibroMeterV2G are two specialized blood fibrosis tests which include direct markers of liver fibrosis. They have been shown to be more accurate than the simple blood fibrosis tests FIB4 and the non‐alcoholic fatty liver disease (NAFLD) fibrosis score (NFS). Aims To directly compare the accuracies of ELF and FibroMeterV2G for the non‐invasive diagnosis of liver fibrosis in NAFLD. Methods Four hundred and seventeen patients with biopsy‐proven NAFLD were enrolled from two tertiary care centres. Four blood fibrosis tests were calculated: ELF, FibroMeterV2G, NFS, and FIB4. Advanced fibrosis F3/4 on liver biopsy (NASH CRN scoring) was the primary endpoint. Results Areas under the receiver operating characteristic (AUROC) curve for advanced fibrosis were not significantly different between the direct markers of liver fibrosis (hyaluronate, PIIINP, TIMP‐1, alpha2‐macroglobulin) and the simple blood fibrosis tests NFS and FIB4. ELF (0.793 ± 0.022) and FibroMeterV2G (0.804 ± 0.021) had significantly higher AUROC than NFS (0.722 ± 0.025, P < .010) and FIB4 (0.739 ± 0.024, P < .020). AUROC for advanced fibrosis and Obuchowski index were not significantly different between ELF and FibroMeterV2G. Algorithms using first ELF or FibroMeterV2G and then liver biopsy in case of undetermined diagnosis provided high diagnostic accuracy for advanced fibrosis: 90% sensitivity, 90% specificity, 93% negative predictive value, 85% positive predictive value, and 90% correct classification. In these algorithms, the rate of liver biopsy was 45.3% with ELF versus 39.3% with FibroMeterV2G (P = .065). Conclusions ELF and FibroMeterV2G have equal accuracy and perform better than the simple FIB4 and NFS tests for the non‐invasive diagnosis of advanced liver fibrosis in patients with NAFLD from tertiary care centres.

show abstract

“…FibroMeter ® has recently reached its third generation Besides, it appears to have a good predictive value towards the occurrence of severe fibrosis in those with NAFLD [66] and chronic hepatitis B or C.…”

Section: [62]mentioning

confidence: 99%

Advances in the diagnosis and treatment of liver fibrosis

Cheng¹,

Wong²

2017

Self Cite

View full text Add to dashboard Cite

Application of the combined FibroMeter vibration‐controlled transient elastography algorithm in Chinese patients with non‐alcoholic fatty liver disease

Abstract: Liver stiffness measurement alone can confidently exclude significant and advanced fibrosis in NAFLD patients. Using FM VCTE in patients with high liver stiffness can increase the positive predictive value to rule in F2-4 and F3-4.

Cited by 47 publications

References 47 publications

Unexpected Rapid Increase in the Burden of NAFLD in China From 2008 to 2018: A Systematic Review and Meta‐Analysis

Unexpected Rapid Increase in the Burden of NAFLD in China From 2008 to 2018: A Systematic Review and Meta‐Analysis

Direct comparison of the specialised blood fibrosis tests FibroMeter^V2G and Enhanced Liver Fibrosis score in patients with non‐alcoholic fatty liver disease from tertiary care centres

Advances in the diagnosis and treatment of liver fibrosis

Contact Info

Product

Resources

About

Application of the combined FibroMeter vibration‐controlled transient elastography algorithm in Chinese patients with non‐alcoholic fatty liver disease

Abstract: Liver stiffness measurement alone can confidently exclude significant and advanced fibrosis in NAFLD patients. Using FM VCTE in patients with high liver stiffness can increase the positive predictive value to rule in F2-4 and F3-4.

Cited by 47 publications

References 47 publications

Unexpected Rapid Increase in the Burden of NAFLD in China From 2008 to 2018: A Systematic Review and Meta‐Analysis

Unexpected Rapid Increase in the Burden of NAFLD in China From 2008 to 2018: A Systematic Review and Meta‐Analysis

Direct comparison of the specialised blood fibrosis tests FibroMeterV2G and Enhanced Liver Fibrosis score in patients with non‐alcoholic fatty liver disease from tertiary care centres

Advances in the diagnosis and treatment of liver fibrosis

Contact Info

Product

Resources

About

Direct comparison of the specialised blood fibrosis tests FibroMeter^V2G and Enhanced Liver Fibrosis score in patients with non‐alcoholic fatty liver disease from tertiary care centres